Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCRx for Tolerance in Kidney Transplant
NCT00498160Phase 2Unknown
- Sponsor
- Talaris Therapeutics
- Start
- Jan 2005
- Primary completion
- Aug 2024
- Modality
- Bone Marrow HSCs, Peripheral Blood HSCs
- Countries
- 1
01
Overview
A Phase 2 trial of FCR001 in kidney transplant rejection, graft-versus-host disease (GVHD), sponsored by Talaris Therapeutics. Status: unknown.
02
Drugs
FCR001
03
Conditions
kidney transplant rejectiongraft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00498160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00498160.